Publications

Search our bibliography using the filters on the right-hand side.

Displaying 201 through 250 of 253 publications.

Earnshaw SR, Beard SM, Lynch NO, Cowell W. Ibandronate in the treatment of postmenopausal osteoporosis: a cost-effectiveness analysis in the UK. Poster presented at the European League Against Rheumatism Annual European Congress of Rheumatology; June 24, 2006.

Zlateva GP, Javitt JC, Earnshaw SR, Pliel AM, Graham CN, Brogan AJ, Shah S, Adamis AP. Cost-effectiveness model for age-related macular degeneration: comparing early and late Macugen® treatment. Poster presented at the 2006 EURETINA Congress; May 21, 2006. Lisbon, Portugal. Previously presented at the 2005 ISPOR 8th Annual European Congress.

Bell CF, Graham JB, Earnshaw SR, Oleen-Burkey M, Castelli-Haley J, Johnson K. Assessing the cost-effectiveness of immunomodulatory therapies for relapsing-remitting multiple sclerosis based on long-term data. Poster presented at the 2006 ISPOR 11th Annual International Meeting; May 20, 2006. Philadelphia, PA.

Earnshaw SR, Moride Y, Moshyk A, Rochon S. Cost-effectiveness of macugen compared to photodynamic therapy (PDT) with verteporfin and standard care in the treatment of subfoveal wet age-related macular degeneration (AMD) in the elderly in Canada. Poster presented at the Third Annual Canadian Joint Therapeutics Congress, Canadian Association for Population Therapeutics; May 13, 2006. Toronto, Canada.

Bell CF, Graham JB, Earnshaw SR, Oleen-Burkey M, Castelli-Haley J, Johnson KP. Assessing the cost-effectiveness of immunomodulatory therapies for relapsing-remitting multiple sclerosis based on long-term data. Value Health. 2006 May 1;9(3):A81-2.

Earnshaw SR, Wilson MR, Joshi AV. Short-term cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage. Value Health. 2006 May 1;9(3):A8.

Earnshaw SR, Graham CN, Amonkar MM, Barr CE. The cost-effectiveness of ibandronate in the treatment of postmenopausal osteoporosis in the US. Value Health. 2006 May 1;9(3):A163.

Earnshaw SR, Graham CN, Amonkar MM, Barr C. The cost-effectiveness of ibandronate in the treatment of postmenopausal osteoporosis in the US. Poster presented at the 2006 ISPOR 11th Annual International Meeting; May 20, 2006. Philadelphia, PA. [abstract] Value Health. 2006 May; 9(3):A163.

Earnshaw SR, Joshi AV, Wilson MR. Cost-effectiveness of recombinant activated factor vii in the treatment of intracerebral hemorrhage: a US managed care perspective. Poster presented at the Academy of Managed Care Pharmacy 18th Annual Meeting; April 7, 2006.

Earnshaw SR, Gricar J. Good practices for high quality decision analytic models. Poster presented at the Academy of Managed Care Pharmacy 18th Annual Meeting; April 6, 2006.

Javitt JC, Earnshaw SR, Graham CN, Brogan AJ, Zlateva GP, Pleil AM. Cost-effectiveness of Macugen versus no treatment in age-related macular degeneration patients. Poster presented at the Association for Research in Vision and Ophthalmology (ARVO) 2006 Annual Meeting; April 2006.

Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med. 2006 Mar 7;144(5):326-36.

Javitt JC, Zlateva GP, Earnshaw SR, Pleil AM, Graham CN, Brogan AJ. Cost-effectiveness model for age-related macular degeneration: comparing Macugen® to Visudyne®. Poster presented at the 2006 World Ophthalmology Congress; February 2006. Previously presented at the ISPOR 8th Annual European Congress.

Earnshaw SR, Wilson MR, Joshi AV. Health plan budget impact analysis of recombinant activated factor VII (rFVIIa) in the treatment of intracerebral hemorrhage. Managed Care Interface. 2006;19(11):39-45.

Earnshaw SR, Javitt JC, Zlateva GP, Pleil AM, Graham CN, Brogan AJ, Shah S, Adamis AP. Cost-effectiveness model for age-related macular degeneration: comparing Macugen® to Visudyne®. Poster presented at the 2005 ISPOR 8th Annual European Congress; November 10, 2005. Florence, Italy.

Earnshaw SR, Javitt JC, Graham CN, Brogan AJ, Zlateva GP, Shah S, Adamis AP. Modeling treatments for subfoveal choroidal neovascularization secondary to age-related macular degeneration: cost-effectiveness methods. Poster presented at the 2005 ISPOR 8th Annual European Congress; November 10, 2005. Florence, Italy. [abstract] Value Health. 2005 Nov; 8(6):A179.

Earnshaw SR, Javitt JC, Zlateva GP, Pleil AM, Graham CN, Brogan AJ, Shah S, Adamis AP. Cost-effectiveness model for age-related macular degeneration: comparing early and late Macugen® treatment. Poster presented at the 2005 ISPOR 8th Annual European Congress; November 10, 2005. Florence, Italy. [abstract] Value Health. 2005 Nov; 8(6).

Pignone M, Earnshaw SR. Cost-effectiveness of aspirin for the primary prevention of cardiovascular events in women. Poster presented at the Society of Medical Decision Making; October 2005.

Earnshaw SR, Candrilli SD, Fernandes AW, Higashi MK. A cost-effectiveness analysis of antibiotic therapy in macrolide-resistant community-acquired pneumonia. Managed Care Interface. 2005 Oct 1;18(10):36-44.

Ettinger B, Earnshaw SR, Graham CN, Amonkar MM, Baran RW. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with ibandronate. Poster presented at the American Society for Bone and Mineral Research (ASBMR) 27th Annual Meeting; September 2005.

Ettinger B, Earnshaw SR, Brogan AJ, Graham CN, Amonkar MM, Baran R. Modeled cost impact of persistence with bisphosphonate therapy for women with postmenopausal osteoporosis. Poster presented at the Academy of Managed Care Pharmacy 17th Annual Meeting & Showcase; April 23, 2005.

Earnshaw SR, Pankaj PA, Candrilli SD, DePlatchett J, Graham CN, Williams L. Impact of pediatric asthma treatment on managed care organization budget. Poster presented at the 2005 AMCP 17th Annual Meeting & Showcase; April 1, 2005.

Earnshaw SR, Patel P, Candrilli SD, Graham CN, Deplatchett J. Impact of treatment on exacerbations in pediatric asthma in managed care organizations. Poster presented at the 2005 AMCP 17th Annual Meeting & Showcase; April 2005.

Earnshaw SR, Brogan AJ, Graham CN, Amonkar MM, Baran R, Hebborn A. The impact of persistency on economic models for bisphosphonate therapy in osteoporosis. Poster presented at the 5th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis; March 26, 2005. Rome, Italy.

Mauskopf JA, Earnshaw SR, Mullins C. Budget impact analysis: review of the state of the art. Expert Rev Pharmacoecon Outcomes Res. 2005 Feb;5(1):65-79.

Earnshaw SR, Beard SM, Gaffney L, Krishnan A, Hogue SL. The impact of premature discontinuation of antidepressant therapy in major depressive disorder in the UK. Poster presented at the 2004 ISPOR 7th Annual European Congress; October 24, 2004. [abstract] Value Health. 2004 Nov; 7(6):A779.

Earnshaw SR, Krishnan A, Hogue SL, Williams JW. The impact of premature discontinuation of antidepressant therapy in major depressive disorder. Poster presented at the 2004 ISPOR 9th Annual International Meeting; May 16, 2004. Arlington, VA. [abstract] Value Health. 2004 May; 7(3):267.

Beard SM, Davies LM, Earnshaw SR, Payne K. Quality and validation standards in healthcare modeling. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research; May 2004.

Pignone M, Earnshaw S, Tice JA, Pletcher M, Wilson M. Aspirin, statins, or both therapies for primary prevention of myccardial infarction: a cost-utility analysis. J Gen Intern Med. 2004 Jan 1;19:121.

Earnshaw SR, Wirth K, Hicks KA. Pilot test of the RTI HIV prevention resource allocation tool. Presented at the Florida Department of Health; August 2003.

Hicks KA, Honeycutt AA, Earnshaw SR, Richter A. A tool for comparing allocations of HIV prevention resources. Presented at the National HIV Prevention Conference; August 2003.

Earnshaw SR, Richter A, Hicks KA, Honeycutt A. The allocation of HIV prevention funds. Poster presented at the 2003 ISPOR 8th Annual International Meeting; May 2003.

Hicks KA, Honeycutt A, Earnshaw SR, Richter A. Models for the efficient allocation of HIV prevention resources. Presented at the Community Planning Leadership Summit for HIV Prevention; March 2003.

Earnshaw SR, Richter A, Hicks K, Honeycutt A. The allocation of HIV prevention funds. Value Health. 2003 Jan 1;6(3):254.

Earnshaw SR, Dennett SL. Integer/linear mathematical programming models: a tool for allocating healthcare resources. Pharmacoeconomics. 2003 Jan 1;21(12):839-51.

Honeycutt AA, Richter A, Earnshaw SR, Hicks KA. A model for allocating HIV prevention resources. Poster presented at the CDC's "Practical Use of CEA" 01158 Grantee Meeting; December 2002.

Hauber BHIV, Earnshaw SR, Spencer MD, Candrilli SD. Estimating the incidence and duration of exacerbations in chronic obstructive pulmonary disease. Poster presented at the 98th Annual Conference of the American Thoracic Society; May 2002.

Spencer MD, Hauber BHIV, Earnshaw SR, Candrilli SD. Estimating lung function decline based on ats staging classifications, and the effect of tobacco smoking in copd patients. Poster presented at the American Thoracic Society 98th International Conference; May 2002.

Earnshaw SR, Richter A, Sorensen SW, Hoerger TJ, Hicks KA, Engelgau M, Thompson T, Narayan KMV, Williamson DE, Gregg E, Zhang P. Optimal allocation of resources across four interventions for type 2 diabetes. Med Decis Making. 2002 Jan 1;22(5):S80-91.

Dombeck M, Earnshaw SR, Candrilli SD, Xuan J, Bakst A, Kirsch JM. Modeling antibiotic efficacy by infectious agent and probability of resistance. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research 4th Annual European Congress; November 2001. [abstract] Value Health. 2001 Sep; 4(6):427.

Alexeyeva I, Mauskopf JA, Earnshaw SR, Gibson JP, Ascher-Svanum H, Ramsey J. A model comparing olanzapine and ziprasidone in patients with schizophrenia. Poster presented at the 2001 ISPOR 6th Annual International Meeting; May 2001. [abstract] Value Health. 2001 Sep; 4(2):148-9.

Alexeyeva I, Mauskopf J, Earnshaw SR, Stauffer VL, Gibson JP, Ascher-Svanum H. Comparing olanzapine and ziprasidone in the treatment of schizophrenia: a case study in modeling. J Med Econ. 2001 Jan 1;4:179-92.

Earnshaw SR, Neighbors DM, Bell LN, Bhattacharyya SK. Treatment guidelines compared to clinical practice for acute muscular low back pain. Poster presented at the 2000 ISPOR 5th Annual International Meeting; May 20, 2000. Arlington, VA.

Neighbors DM, Earnshaw SR, Bell L, Bhattacharyya SK. A model to perform economic evaluations of interventions for acute muscular low back pain. Poster presented at the 2000 ISPOR 5th Annual International Meeting; May 20, 2000. Arlington, VA.

Earnshaw SR, Dennett SL, Richter A, Mauskopf JA. The use of integer/linear programming models in pharmacoeconomics. Presented at the 2000 ISPOR 5th Annual International Meeting; May 2000.

Earnshaw SR. Determining an allocation of trainers and field representatives to training sites and start times. Presented at the Business and Financing Studies for the Agency for Health Care Policy and Research; January 1999. Washington, DC.

Spencer DL, Reed (Earnshaw) SJ, Atkinson D, Kalsbeek WD. Design of a survey to inform state health decision making: a collaborative effort. Am J Prev Med. 1997 Nov 1;13(6 Suppl):69-74.

Reed (Earnshaw) SR. Application of operations research techniques to survey research. Presented at the US Department of Commerce, Bureau of the Census; October 1997. Charlotte, NC.

Reed (Earnshaw) SJ, Reed JH. The use of statistical quality control charts in monitoring interviewers. Proceedings of the Survey Research Methods Section, American Statistical Association. 1997 Jan;893-8.

Reed (Earnshaw) SR, Reed JH, Stuhldreher TJ. Transaction costs, taxes, and portfolio revision. J Contemp Bus Issue. 1997;5:40-8.